MaxCyte Licenses Cell Engineering Platform to TG Therapeutics for Autoimmune Disease Therapy
Why we think this is good
The key factors that contribute to the GOOD sentiment score are: the strategic platform license agreement with TG Therapeutics, a leading biopharmaceutical company, which validates the capabilities of MaxCyte's cell engineering platform; the agreement will generate annual licensing fees and program-related revenue for MaxCyte, providing a new revenue stream; and MaxCyte's technology has been integral to the manufacturing of allogeneic T cell immunotherapies, demonstrating the value and versatility of the company's platform.
Key Points
- MaxCyte grants TG Therapeutics non-exclusive rights to use its Flow Electroporation® technology and ExPERT™ platform
- Agreement supports the development of TG Therapeutics' allogeneic CD19 CAR T cell therapy program, azer-cel, for autoimmune diseases
- MaxCyte will receive annual licensing fees and program-related revenue
- TG Therapeutics recently obtained global rights for azer-cel and received FDA clearance for a Phase 1 trial in progressive multiple sclerosis
- MaxCyte's technology has been integral to the manufacturing of allogeneic T cell immunotherapies
Summary
MaxCyte, Inc. has entered into a strategic platform license agreement with TG Therapeutics, a fully integrated, commercial stage, biopharmaceutical company. Under the terms of the agreement, TG Therapeutics obtains non-exclusive rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to support the development and commercialization of azer-cel, TG Therapeutics' allogeneic CD19 CAR T cell therapy program for the treatment of autoimmune diseases.
MaxCyte will receive annual licensing fees and program-related revenue from the agreement. TG Therapeutics recently obtained global rights for azer-cel from Precision BioSciences and has received FDA clearance to commence a Phase 1 trial in progressive forms of multiple sclerosis. MaxCyte's technology has been integral to the manufacturing of allogeneic T cell immunotherapies and was efficiently transferred from Precision BioSciences to TG Therapeutics.
The agreement demonstrates the continued adoption and importance of MaxCyte's cell engineering platform in the rapidly growing cell therapy market. However, the non-exclusive nature of the agreement and the lack of financial details limit the ability to fully assess the potential impact on MaxCyte's business and valuation.